---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024707"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2026-05-21T10:04:26+00:00"
generated_at: "2026-05-21T10:05:42.625895+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR

## Summary
- All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
- CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.
- All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.
- Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.
- Next NEXICART-2 data update expected late September 2026.

## SEC filing metadata
- accession: 0001493152-26-024707
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2026-05-21T10:04:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/0001493152-26-024707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024707
- JSON: https://secwatch.observer/filing/0001493152-26-024707.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.